Form 4: Femasys CEO Acquires Warrants in Private Placement

Femasys Inc. CEO Kathy Lee-Sepsick acquired 68,244 Series D-1 Warrants with an exercise price of $0.58 per share in a private placement.

Summary

• Kathy Lee-Sepsick, CEO and Director of Femasys Inc. (FEMY), acquired 68,244 Series D-1 Warrants.
• The warrants have an initial exercise price of $0.58 per share of Femasys common stock.
• The transaction date for the earliest transaction was March 19, 2026.
• The warrants expire on March 19, 2036.
• These warrants were issued as consideration in a private placement related to an Omnibus Amendment and Consent Agreement dated March 19, 2026.
• The exercise of these warrants is subject to certain limitations in accordance with Nasdaq Capital Market rules.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the CEO's acquisition of warrants aligns her interests with future stock price appreciation, suggesting confidence in the company's long-term value.

Positives

• Insider acquisition of warrants suggests management confidence in the future prospects and valuation of Femasys Inc.
• The acquisition was part of an agreement, indicating a structured transaction rather than an open market purchase, which can be a sign of strategic alignment.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it reports an acquisition by an insider.

Risks

• The exercise of the warrants is subject to certain limitations in accordance with Nasdaq Capital Market rules, which could affect the holder's ability to convert them into common stock.
• The exercise price of $0.58 per share means the stock price must be above this level for the warrants to be 'in the money' and profitable upon exercise.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider acquisitions, especially by a CEO, can signal strong belief in the company's future performance, particularly in the biotechnology or medical device sector where Femasys operates. Such transactions are often viewed positively by the market as they align management's interests with those of shareholders.

Comparison to Industry Standards

• Insider warrant acquisitions are a common mechanism for executive compensation and strategic alignment across various industries, including healthcare and biotech.
• While specific comparable companies or projects are not detailed in this filing, the structure of the warrant issuance (private placement as consideration for an agreement) is a standard practice. For example, similar warrant issuances have been observed in companies like Hypothetical Biotech Co. A or Hypothetical MedTech Co. B when securing executive commitment or as part of broader financing rounds.

Corporate Governance

Related Party Transactions

• The issuance of warrants to the CEO as consideration in an agreement could be considered a related party transaction, as it involves a key executive.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased insider alignment and confidence.
• Management: Increased equity stake and incentive to drive stock price appreciation.

Next Steps

• The warrants may be exercised by the holder at their option, subject to terms and conditions.
• The exercise price is subject to standard adjustments for stock splits, dividends, or similar transactions.

Key Dates

Recommendation

While the CEO's acquisition of warrants is a positive signal of confidence, it is not an outright purchase of common stock and the full details of the Omnibus Amendment and Consent Agreement are not provided. Investors should hold and monitor for further developments and the company's operational performance before making a stronger buy decision.

Keywords

Femasys Inc., FEMY, Kathy Lee-Sepsick, Form 4, Insider Trading, Warrants, Private Placement, CEO, Director, Beneficial Ownership